Cancer Research SABCS  Sign up for Cancer Research eTOC's
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 52, 3182-3188, June 1, 1992]
© 1992 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pommier, G. J.
Right arrow Articles by Remacle-Bonnet, M. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pommier, G. J.
Right arrow Articles by Remacle-Bonnet, M. M.

Potential Autocrine Role of Insulin-like Growth Factor II during Suramin-induced Differentiation of HT29-D4 Human Colonic Adenocarcinoma Cell Line1

Gilbert J. Pommier2, Françoise L. Garrouste, Fatima El Atiq, Monique Roccabianca, Jacques L. Marvaldi and Maryse M. Remacle-Bonnet

Laboratoire d'Immunopathologie, Faculté de Médecine [G. J. P., F. L. G., F. E. A.], and Institut de Chimie Biologique, CNRS-URA 202, Faculté des Sciences [M. R., J. L. M., M. M. R. B.], Marseille, France

Suramin, a drug that binds to several types of growth factors, has been previously shown to induce the enterocyte-like differentiation of HT29-D4 human colonic adenocarcinoma cells, suggesting that growth factors are involved in such a process. Undifferentiated HT29-D4 cells release insulin-like growth factor II (IGF-II) into the culture medium that is totally complexed to heterogeneous IGF binding proteins (IGFBP) expressing high affinities for this growth factor (Kda = 0.02 mM and Kdb = 1.4 nM). These complexes do not allow IGF-II to bind to HT29-D4 cell surface type I IGF receptors, as evidenced by using 125I-IGF-II-IGFBP complexes. However, the addition of 40–100 µg/ml suramin, i.e., concentrations identical to the ones that are able to induce HT29-D4 cell differentiation, induces the release of IGF-II from IGF-II-IGFBP complexes, thereby allowing IGF-II to bind to the cell surface receptors. At such concentrations, suramin is indeed unable to alter IGF-II binding to HT29-D4 cells, a capacity that is observed only for concentrations higher than 200 µg/ml. Thus, suramin might have the unusual capacity to allow the establishment of an IGF-II autocrine loop involved in HT29-D4 cell differentiation. Consistent with this hypothesis is the fact that exogenously applied IGF-I (2.5 µg/ml) or agonist monoclonal antibody {alpha}IR-3 (2.5 µg/ml), which can bypass IGFBP present in the culture medium, induces part of HT29-D4 cell differentiation that is characterized by an important carcinoembryonic antigen release and the induction of numerous intercellular cysts with microvilli.

1 Supported by grants from the Association pour la Recherche sur le Cancer and Ligue Nationale Française contre le Cancer.

2 To whom requests for reprints should be addressed, at Laboratoire d'Immunopathologie, Faculté de Médecine, 27, Boulevard Jean Moulin, 13385 Marseille Cedex 5, France.

Received 11/ 5/91. Accepted 3/20/92.




This article has been cited by other articles:


Home page
J. Nutr.Home page
E. J. Kim, I.-J. Kang, H. J. Cho, W. K. Kim, Y.-L. Ha, and J. H. Y. Park
Conjugated Linoleic Acid Downregulates Insulin-Like Growth Factor-I Receptor Levels in HT-29 Human Colon Cancer Cells
J. Nutr., August 1, 2003; 133(8): 2675 - 2681.
[Abstract] [Full Text] [PDF]


Home page
ScienceHome page
H. Cui, M. Cruz-Correa, F. M. Giardiello, D. F. Hutcheon, D. R. Kafonek, S. Brandenburg, Y. Wu, X. He, N. R. Powe, and A. P. Feinberg
Loss of IGF2 Imprinting: A Potential Marker of Colorectal Cancer Risk
Science, March 14, 2003; 299(5613): 1753 - 1755.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
L. Shalamanova, B. Kubler, J.-G. Scharf, and T. Braulke
MDCK cells secrete neutral proteases cleaving insulin-like growth factor-binding protein-2 to -6
Am J Physiol Endocrinol Metab, December 1, 2001; 281(6): E1221 - E1229.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
M. Lehmann, F. Andre, C. Bellan, M. Remacle-Bonnet, F. Garrouste, F. Parat, J.-C. Lissitsky, J. Marvaldi, and G. Pommier
Deficient Processing and Activity of Type I Insulin-Like Growth Factor Receptor in the Furin-Deficient LoVo-C5 Cells
Endocrinology, September 1, 1998; 139(9): 3763 - 3771.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
F. L. Garrouste, M. M. Remacle-Bonnet, M. M.-A. Lehmann, J. L. Marvaldi, and G. J. Pommier
Up-Regulation of Insulin/Insulin-Like Growth Factor-I Hybrid Receptors during Differentiation of HT29-D4 Human Colonic Carcinoma Cells
Endocrinology, May 1, 1997; 138(5): 2021 - 2032.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1992 by the American Association for Cancer Research.